Article Text

Download PDFPDF
Infrequent expression of CD15 by classical Hodgkin's lymphomas in Taiwan
  1. Shih-Sung Chuang1,2,3
  1. 1Department of Pathology, Chi-Mei Medical Center, Tainan, Taiwan
  2. 2Department of Pathology, Taipei Medical University, Taipei, Taiwan
  3. 3Department of Pathology, National Taiwan University, Taipei, Taiwan
  1. Correspondence to Professor Shih-Sung Chuang, Department of Pathology, Chi-Mei Medical Centre, 901 Chung-Hwa Road, Yong-Kang District, Tainan 71004, Taiwan; cmh5301{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Hodgkin's lymphoma (HL) is a B cell neoplasm and is classified into two categories: nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) and classical Hodgkin's lymphoma (CHL). CHL is a clonal lymphoid neoplasm originating from germinal centre B cells; the diagnosis is based on typical Hodgkin and Reed-Sternberg (HRS) giant cells in an inflammatory background. Histologically, four histological subtypes of CHL have been identified: nodular sclerosis, lymphocyte rich, mixed cellularity and lymphocyte-depleted.1 Immunohistochemically, HRS cells in nearly all cases are positive for CD30 and for CD15 in the majority (75–85%) of cases according to the 2008 WHO classification.1 ,2 The histological diagnosis of CHL in most instances is straightforward, particularly with the aid of immunohistochemistry. Other than the prerequisite of CD30 expression by HRS cells, CD15 is frequently referred to as a ‘positive’ marker for diagnosis. Apart from diagnostic importance, CD15 expression is of prognostic value. Lack of CD15 expression in CHD has been reported to be a poor prognostic factor in patients with CHL.3 ,4

In the author's experience in Taiwan, the frequency of CD15 expression in CHL is low, which prompted the author to systemically investigate the prevalence of …

View Full Text


  • Handling editor Cheok Soon Lee

  • Funding Ministry of Science and Technology of the People's Republic of China (MOST 103-2314-B-384 -003).

  • Competing interests None declared.

  • Ethics approval IRB at Chi-Mei Medical Center, Tainan, Taiwan.

  • Provenance and peer review Not commissioned; externally peer reviewed.